ArticleClinics (Sao Paulo, Brazil)2024

Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer.

Qi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.